Navigation Links
Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Date:10/3/2007

er-blinded, within-cohort randomized, placebo-controlled study being conducted in up to 75 treatment-naive patients with genotype 1 hepatitis C virus. The primary objective is to assess the safety, tolerability and pharmacokinetics of R7128 in combination with Pegasys plus Copegus. The secondary objective of Part 3 is to evaluate the short-term change in HCV RNA. The study will include two to three oral doses of R7128 (500 mg to 1500 mg) that are being administered twice-daily with Pegasys plus Copegus for 28 days.

Pegasys and Copegus are registered trademarks of Roche.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that adverse events could cause the cessation of the Phase 1 study and/or our development of R7128, the risk that our collaboration with Roche will not continue or will not be successful, the risk that the on-going or anticipated clinical trials for any one or more of our product candidates will not be successful or will not provide meaningful data and the risk that any one or more of our product candidates will n
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... of the "Infectious Disease Diagnostics Market by Product, ... report to their offering. , The ... CAGR of 7.9% to reach $18,156.2 million by 2019 ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... Diagnostics Market by Allergen Source, Product & by End User ... The global allergy diagnostics market is valued ... at a CAGR of 12.67%, to reach $2,230.72 million by ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "X-Ray Detectors Market by Detector Type, Applications & by FPD ... their offering. , The X-ray detectors market ... technological advancements since its inception, such as a shift from ...
Breaking Medicine Technology:Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3Global X-Ray Detectors (Flat Panel, Computed Radiography, CCD, Line-Scan) Market - Forecast to 2019 2Global X-Ray Detectors (Flat Panel, Computed Radiography, CCD, Line-Scan) Market - Forecast to 2019 3
... , , ... KERX ) today announced results of the Open Label ... of elevated serum phosphorous levels, or hyperphosphatemia, in patients with ... in Taiwan, enrolled 29 of the 37 Taiwanese patients that ...
... , , , ... today announced results from a Phase II trial of regorafenib (BAY 73-4506), ... in a 31 percent partial response rate and 50 percent stabilization rate ... in an oral session at the joint 15th Congress of the European ...
Cached Medicine Technology:Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 2Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 3Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia 4Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... January 22, 2015 EBSCO Information Services ... are expanding their relationship in an effort to further promote ... world. While EBSCO has long made AMA journals available via ... agent for The JAMA Network. , Long known ...
(Date:1/22/2015)... 22, 2015 Compare-autoinsurance.org has released a new blog ... an auto insurance policy . , Some types of ... should check the newly released blog post to see if their ... dangerously damaged vehicles are some of the cars that cannot be ...
(Date:1/22/2015)... USA (PRWEB) January 22, 2015 State ... statewide data management system with support from GEOSYSTEMS, a ... The new solution will leverage Hexagon Geospatial’s ERDAS ... vector data as well as point clouds and documents. ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... DaVita,s Efforts in Corporate Social Responsibility and Support ... Calif., May 22 DaVita Inc. (NYSE: ... care services for those diagnosed with chronic kidney ... and marketing departments received eight Hermes Creative Awards, ...
... breast cancer had additional malignant tumors found only by ... Medical Center. , A total of 199 patients ... found additional, unsuspected cancers in the ipsilateral breast (the ... 16% of patients; we found cancers in the contralateral ...
... issued the,following press release: , ... flurry of panic about,the H1N1 (swine influenza). School ... even suggested closing the border with Mexico,where approximately three ... every day. The panic certainly was fueled by ...
... CyberKnife Centers Are Meeting Increasing Demand for ... TechnologiesSUNNYVALE, Calif., May 22 Accuray Incorporated ... leader in the field of radiosurgery, announced ... patient throughput using their recently installed, next ...
... Effort Addressing the Leading Cause of Maternal Mortality to ... Every year, more than half a million of the ... crisis that has seen little to no improvement over ... by Pathfinder International capitalized on groundbreaking new technologies in ...
... Reach $500 Million by 2014PRINCETON, N.J., May 22 ... federal funds next year and more than $500 million ... rules proposed to take effect in October, according to ... Economics department examined the impact of three provisions under ...
Cached Medicine News:Health News:DaVita Wins Eight Hermes Creative Awards Recognizing Excellence in Communications and Marketing 2Health News:DaVita Wins Eight Hermes Creative Awards Recognizing Excellence in Communications and Marketing 3Health News:H1N1: What You Should Know 2Health News:H1N1: What You Should Know 3Health News:Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife 2Health News:Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife 3Health News:Next Generation CyberKnife Increases Patient Throughput at Philadelphia CyberKnife 4Health News:New Initiative Poised To Reduce Maternal Mortality Rates By More Than 25 Percent 2Health News:N.J. Hospitals Face $97 Million in Medicare Cuts 2Health News:N.J. Hospitals Face $97 Million in Medicare Cuts 3
BD Vacutainer® Fluoride Tubes - Plastic...
Inquire...
Inquire...
... The inner wall of the serum ... particles, these particles activate the coagulation process. ... gel in the base of the tube; ... barrier between the serum and the blood ...
Medicine Products: